Andrew Nguyen

发表

Diagnostic value of 68Ga‐DOTATATE PET‐CT imaging for staging of ER+/PR+ HER2‐ breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F‐FDG PET‐CT in a prospective pilot trial

Julia Chen, E. Lim, R. Dear, 2021, Journal of medical imaging and radiation oncology.

177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

C. Gedye, E. Hovey, P. Eu, 2021, The Journal of Nuclear Medicine.

177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

C. Gedye, E. Hovey, P. Eu, 2022 .

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).

Trevor J Pugh, T. Pugh, P. Eu, 2020, European urology oncology.

3-Year Freedom from Progression After 68Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial

P. Stricker, A. Kneebone, M. Roberts, 2019, The Journal of Nuclear Medicine.

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.

H. Woo, N. Lawrentschuk, D. Murphy, 2021, European urology.

Event-free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups.

M. Chatfield, P. Stricker, T. Eade, 2022, BJU international.

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

M. Stockler, C. Gedye, E. Hovey, 2023, Therapeutic advances in medical oncology.

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy

M. Stockler, A. O. Yam, A. Joshua, 2022, The Journal of Nuclear Medicine.

64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial

E. Lim, A. Malaroda, R. Dear, 2022, Pharmaceuticals.

Pilot Trial Comparing the Performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/CT in the Detection of Prostate Cancer Recurrence in Men with Rising PSA Following Radical Prostatectomy

P. Stricker, P. Lin, K. Fullard, 2021 .

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

M. Stockler, P. Eu, A. O. Yam, 2022, The Journal of Nuclear Medicine.

The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)

M. Stockler, P. Wilson, P. Eu, 2022, The Journal of Nuclear Medicine.

Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).

P. Eu, A. O. Yam, A. Joshua, 2021 .

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database

M. Frydenberg, J. Yaxley, J. Calais, 2023, The Journal of Nuclear Medicine.

Treatment Response Imaging in Prostate Cancer.

M. Swiha, Andrew Nguyen, Andrei Gafita, 2024, PET clinics.

Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT.

A. Kneebone, G. Hruby, M. Crumbaker, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.